Pharma channel feed

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

6 years ago
FDA+

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 years ago
China

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

6 years ago

Af­ter years of busi­ness and law­suit-fu­eled de­cline, is a Te­va turn­around in sight?

6 years ago

No­var­tis chris­tens new UK HQ in West Lon­don, kick­ing off its big in­clisir­an CV tri­al

6 years ago
People
R&D

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

6 years ago
R&D

Lil­ly, No­vo Nordisk fight in­sulin biosim­i­lars with tweaks to FDA draft guid­ance

6 years ago
FDA+

With block­buster dreams, Ex­elix­is is look­ing for some re­demp­tion for cabo in prostate can­cer. It won’t be easy

6 years ago
R&D

Record lev­els of VC fi­nanc­ing and R&D boom left bio­phar­ma com­pa­nies clam­or­ing for space. How bad is it?

6 years ago

Bio­gen shares rock­et up as My­lan's chal­lenge to Tec­fidera patents is slapped down

6 years ago

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

6 years ago
Deals
R&D

Too slow to warn: Sanofi in­dict­ed over old an­ti-epilep­tic drug tied to birth de­fects

6 years ago
FDA+

Gilead surges wild­ly as world scram­bles to counter a like­ly coro­n­avirus pan­dem­ic while GSK pitch­es in on vac­cine R&D cam­paign

6 years ago
Coronavirus

Aim­mune wins ap­proval for peanut im­munother­a­py, charges 10k+

6 years ago
FDA+

Biotech was big in 2019, but here's one record no one want­ed to see bro­ken: Most bank­rupt­cies

6 years ago

Out­go­ing CEO Jeff Lei­den takes vic­to­ry lap as Ver­tex's Trikaf­ta stuns Wall Street

6 years ago
R&D

Vas Narasimhan wants No­var­tis to have a big fo­cus on Chi­na. Here’s what that looks like

6 years ago
China

Mike Bloomberg joins a grow­ing cho­rus of De­mo­c­ra­t­ic pres­i­den­tial can­di­dates threat­en­ing to go af­ter drug patents

6 years ago
People

J&J's Spra­va­to gets no love from NICE, jeop­ar­diz­ing its prospects in the UK

6 years ago

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

6 years ago
R&D

As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

6 years ago
R&D

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

6 years ago

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

6 years ago

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

6 years ago
FDA+
First page Previous page 260261262263264265266 Next page Last page
A service from the Financial Times